Found 120 clinical trials
C3711005
The study will evaluate the effect of coadministration of a range of doses of DGAT2i with 1 dose of ACCi, on hepatic steatosis and the ability of DGAT2i to mitigate ACCi-induced elevations in
- 48 views
- 14 Sep, 2021
- 4 locations
Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics
Metabolic diseases of the liver are silent affections whose morbidity is important. About 70% of patients with type 2 diabetes (T2D) are concerned. Of these, 50% develop clinically significant lesions (including non-alcoholic steatohepatitis or NASH) as they are associated with an increased risk of complications; and 15% progress to severe …
- 0 views
- 12 Apr, 2021
- 2 locations
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Lipodystrophies are rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications. Hepatic steatosis is a common
- 2 views
- 13 Jun, 2021
- 2 locations
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference
). Even if the liver fibrosis is the key pathological feature of progressive liver disease, the accumulation of excessive hepatic triglyceride, hepatic steatosis, is today recognized as an
- 0 views
- 30 Aug, 2021
- 8 locations
Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I
; and the prevention of increased liver steatosis based on ultrasound with elastography.
- 33 views
- 29 Apr, 2021
- 1 location
Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to examine the effect of metformin on biochemical and histological findings in NAFLD patients with insulin resistance syndrome.
- 8 views
- 07 Nov, 2020
- 1 location
Fatty Liver and Ectopic Fat in Overweight and Obese Patients
The aim of the study is to find new clinico-biological and medical imaging parameters associated with non alcoholic steatohepatitis in overweight and obese patients.
- 2 views
- 07 Nov, 2020
- 1 location
Pathophysiology of Uric Acid Nephrolithiasis
This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results. Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on excess fatty acid …
- 8 views
- 29 May, 2021
- 1 location
Lifestyle Modification for MAFLD Based on TTM
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due …
- 0 views
- 13 May, 2021
- 1 location
NAFLD Primary Care
simple steatosis, however in about 15-30% non-alcoholic steatohepatitis (NASH) develops, which leads to an overall increase in morbidity and mortality due to the progression to fibrosis, cirrhosis and
- 0 views
- 23 Jun, 2021
- 1 location